Zomedica Corp. (ZOMDF) — SEC Filings
Zomedica Corp. (ZOMDF) — 34 SEC filings. Latest: 10-Q (Nov 4, 2025). Includes 16 8-K, 8 DEFA14A, 6 10-Q.
View Zomedica Corp. on SEC EDGAR
Overview
Zomedica Corp. (ZOMDF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Zomedica Corp. reported a net loss of $77.328 million for the nine months ended September 30, 2025, a significant increase from the $39.788 million net loss in the prior year period, primarily driven by a substantial impairment expense of $55.833 million. Despite this, net revenue increased to $21.5
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Zomedica Corp. is neutral.
Filing Type Overview
Zomedica Corp. (ZOMDF) has filed 6 10-Q, 16 8-K, 8 DEFA14A, 2 10-K, 2 DEF 14A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of ZOMDF's 30 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $21,559,000 |
| Net Income | -$77,328,000 |
| EPS | N/A |
| Debt-to-Equity | 0.09 |
| Cash Position | $7,496,000 |
| Operating Margin | -367.33% |
| Total Assets | $130,905,000 |
| Total Debt | $11,217,000 |
Industry Context
Zomedica operates in the animal health diagnostics and therapeutics market. This sector is characterized by increasing pet ownership, a growing demand for advanced veterinary care, and significant investment in R&D. Competition comes from established players and emerging companies offering innovative diagnostic tools and treatments. The industry is also subject to regulatory oversight regarding product safety and efficacy.
Top Tags
corporate-governance (10) · financial-reporting (6) · 8-k (5) · 10-Q (4) · Zomedica (4) · financials (3) · financial-statements (3) · filing (3) · financial-condition (3) · shareholder-vote (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $77.328M | More than doubled from $39.788M in 2024 for the nine months ended September 30. |
| Impairment Expense | $55.833M | Major contributor to the increased net loss for the nine months ended September 30, 2025. |
| Net Revenue | $21.559M | Increased from $19.390M in 2024 for the nine months ended September 30, showing 11.19% growth. |
| Total Assets | $130.905M | Decreased significantly from $207.360M at December 31, 2024. |
| Accumulated Deficit | $295.243M | Increased from $217.915M at December 31, 2024, indicating persistent unprofitability. |
| Cash and Cash Equivalents | $7.496M | Slight increase from $7.021M at December 31, 2024. |
| Common Shares Outstanding | 979,949,668 | Remained constant as of September 30, 2025, and December 31, 2024. |
| Q2 2025 Revenue | $5.1M | Increased by 15.9% from Q2 2024 |
| Q2 2025 Net Loss | -$3.5M | Reduced from -$4.2M in Q2 2024 |
| Revenue Growth | 15.9% | Year-over-year increase in Q2 2025 revenue |
| Cash and Equivalents | $105.2M | As of June 30, 2025, providing liquidity |
| R&D Expenses | $1.1M | Increased by 10% in Q2 2025, showing investment |
| Reporting Period End | 20250331 | The 10-Q covers financial data up to this date. |
| Filing Date | 20250515 | The date the report was officially submitted to the SEC. |
| Central Index Key | 0001684144 | Unique identifier for Zomedica Corp. in SEC filings. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zomedica Corp. (ZOMDF)?
Zomedica Corp. has 34 recent SEC filings from Jan 2024 to Nov 2025, including 16 8-K, 8 DEFA14A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZOMDF filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Zomedica Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zomedica Corp. (ZOMDF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zomedica Corp.?
Key financial highlights from Zomedica Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZOMDF?
The investment thesis for ZOMDF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zomedica Corp.?
Executive information for Zomedica Corp. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Zomedica Corp. stock?
Of ZOMDF's 30 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Zomedica Corp.?
Forward guidance and predictions for Zomedica Corp. are extracted from SEC filings as they are enriched.